Deutsche Bank Initiates Coverage On Amylyx Pharma with Buy Rating, Announces Price Target of $36
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg has initiated coverage on Amylyx Pharmaceuticals with a Buy rating and set a price target of $36 for the company's stock.
December 12, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Deutsche Bank has initiated coverage on Amylyx Pharmaceuticals with a Buy rating and a price target of $36, which could positively influence the stock's performance in the short term.
Analyst ratings, especially from major banks like Deutsche Bank, can significantly impact a stock's performance. A Buy rating suggests confidence in the company's future performance and the price target of $36 indicates a potential upside from the current trading price. This can attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100